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Objectives: Surgical resection after preoperative chemotherapy in patients with
non–small cell lung cancer might only be best for patients who are responders. We
compared positron emission tomographic scanning with 2-fluoro-2-deoxy-D-glucose
(FDP-PET scanning) with computed tomographic scanning to evaluate their ability
to predict this response for the primary tumor, N1 and N2 lymph nodes.
Methods: All patients with non–small cell lung cancer who had an initial FDP-PET
scan staging with tissue biopsy, neoadjuvant chemotherapy, repeat FDP-PET scan-
ning, and repeat biopsies were prospectively studied.
Results: There were 34 patients (24 men; median age, 64 years). Eleven patients had
N2 disease, and 7 had N1 disease. Twenty-seven patients received chemotherapy,
and 7 patients received chemotherapy and radiation. All but 9 patients underwent
resection. Statistical analysis showed FDP-PET scanning to be more specific (P 
.0001), to have a higher positive predictive value (P  .0018), and to have a higher
negative predictive value (P  .0001) than computed tomographic scanning for
predicting residual tumor at the primary site. FDP-PET scanning was more sensitive
(P  .0001) and more accurate (P  .0001), had a higher positive predictive value
(P  .0001), and had a higher negative predictive value (P  .0002) than computed
tomographic scanning for paratracheal nodes (number 2 and 4 lymph nodes).
FDP-PET scanning had a higher positive predictive value (P  .0001) than com-
puted tomographic scanning for the other N2 (numbers 5, 6, 7, 8, and 9) lymph
nodes.
Conclusions: Repeat FDP-PET scanning is more specific and has a higher positive
predictive value and negative predictive value than computed tomographic scanning
for detecting residual tumor in the lung in patients with non–small cell lung cancer
who have received preoperative chemotherapy. It is more sensitive and accurate for
paratracheal N2 nodes as well. However, there is no significant difference in its
detection of N1 lymph nodes.
Over the last several years, positron emission tomographic (PET)scanning with 2-fluoro-2-deoxy-D-glucose (FDG-PET) has beenused to help clinically staged patients with non–small cell carci-noma (NSCLC).1-15 Despite these articles, the precise role ofFDG-PET scanning for these patients is yet to be determined.Only a few studies have analyzed the use of FDG-PET scanning16
after neoadjuvant therapy in patients with non–small cell bronchogenic malignancy.
This issue is becoming more and more important because more patients with lung
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cancer are undergoing preoperative chemotherapy, radio-
therapy, or both. Most general thoracic surgeons agree that
if patients have recalcitrant N2 disease after neoadjuvant
therapy, surgical resection offers little advantage. The
5-year survival after resection is 50% for those who respond
and only 15% for those who still have cancer in the N2
nodes. Therefore repeat biopsy of previously involved nodal
stations after neoadjuvant therapy is crucial for appropriate
patient selection. These procedures, which include redo
transesophageal ultrasound, redo mediastinoscopy, anterior
mediastinotomy, video-assisted thoroscopy, and/or thora-
cotomy have morbidity and cost. A noninvasive test that
could accurately predict who was downstaged or who was a
responder would provide powerful information. Unfortu-
nately, computed tomographic (CT) scans and chest roent-
genograms are poor predictors of actual pathologic re-
sponse. Therefore we wanted to evaluate the sensitivity,
specificity, accuracy, positive predictive value, and negative
predictive value of FDG–PET. Our goal was to compare
FDG-PET with CT scanning to determine whether it added
important information or if it was merely a superfluous and
expensive examination. We tried to evaluate each aspect of
the staging system and compared the results of both CT and
FDG-PET in predicting the patient’s tumor response (T
status) and N1 and N2 nodal status.
Methods
From May 2000 to March 2002, we prospectively studied all
consecutive patients who had biopsy-proven NSCLC, had a CT
scan of the chest and upper abdomen, had a whole-body FDG-PET
scan, underwent preoperative chemotherapy, and then were re-
staged with tissue biopsies or underwent thoracotomy, complete
thoracic lymphadenectomy, and pulmonary resection.
All FDG-PET scans were performed on a dedicated ECAT
EXACT PET scanner (CTI). The scans were performed after
injection of 370 MBq of FDG intravenously, and the chest CT was
available at the time for correlation. The patients were advised not
to eat or drink fluids containing calories for 4 hours before arrival
at the PET center. This was confirmed with the patient before
injection of the radiotracer. Any suspicious lymph node, nodule, or
mass on the CT scan or that was visualized by means of FDG-PET
was further evaluated by means of conventional radiography or
biopsy. Patients were then clinically staged, and they received
neoadjuvant therapy with chemotherapy (with or without radia-
tion). All patients then underwent repeat staging with a second CT
scan of the chest and a repeat FDG-PET scan. Any suspicious
lesion or lymph node determined by means of FDG-PET or CT
scanning underwent biopsy. Patients whose test results were ini-
tially negative for N2 disease (including those whose results were
initially positive and then rendered negative by neoadjuvant ther-
apy) underwent thoracotomy. Complete thoracic lymphadenec-
tomy was performed, and frozen-section analysis were made. If the
N2 nodes were negative in frozen-section analysis, pulmonary
resection was performed. If the N2 lymph nodes were still malig-
nant, pulmonary resection was not performed because no survival
benefit has been shown, and the increased morbidity of pulmonary
resection was avoided. Patients were excluded from this series if
they did not have an initial FDG-PET scan before their neoadju-
vant therapy or if the FDG-PET scan was not performed on a
dedicated camera. All patients were staged by using the TNM
classification system, as described by Mountain.17
Suspicious lymph nodes on FGD-PET scans were defined as
any node with a mean standard uptake value (SUV) of greater than
3.0. This value was chosen on the basis of work previously
performed and based on our center’s mean mediastinal background
SUV of 1.63 (SD  0.31). Suspicious lymph nodes on CT scan-
ning were defined as any N2 lymph node that was larger than 1.0
cm in any axis. This value was chosen to ensure that any lymph
node that was even slightly enlarged on CT, whether in the short
or long axis, underwent biopsy. Any indeterminate lesion outside
the thorax underwent further investigation, biopsy, or both. The
same criterion was used after the completion of the neoadjuvant
protocol. However, if the initial FDG-PET scan questioned a
lesion, a biopsy of the lesion showed it to be negative, and repeat
FDG-PET showed the lesion to have the same SUV or less, repeat
biopsy was not performed. However, if the lesion had a higher
SUV or if the patient had a new suspicious lesion, it underwent
biopsy.
Patients who underwent chemotherapy for biopsy-proven N2
disease underwent rebiopsy of the same N2 node after chemother-
apy. If that node was still positive, the patient did not undergo
thoracotomy but was included in this trial. Patients who were
entered into the American College of Surgeons Oncology Group
S9900 trial and who were randomized to chemotherapy were also
included in this study. All patients who underwent thoracotomy
and who had resection of their pulmonary lesion with intent to cure
underwent complete thoracic lymphadenectomy. Pulmonary resec-
tion was performed by means of pneumonectomy, lobectomy, or
segmentectomy only.
All results are reported as ranges with medians. Comparisons
were made by using a Kruskal-Wallis 2 test and comparison of
population proportion with a Fisher exact test if needed. Table 1
depicts the definitions and calculations used to determine the
sensitivity, specificity, accuracy, negative predictive value, and
positive predictive value. The internal review board at the Univer-
sity of Alabama at Birmingham approved this study.
Results
The study included 34 patients (24 men) with a median age
of 64 years (range, 43-76 years). All patients had biopsy-
proven NSCLC, as determined with transthoracic or trans-
bronchial needle biopsy. In addition, 25 patients had medi-
astinoscopy, 7 underwent transesophageal ultrasonography
and fine-needle aspiration (FNA) of N2 lymph nodes, 3 had
TABLE 1. Definitions
Sensitivity  TP/TP  FN
Specificity  TN/TN  FP
Accuracy  TP  TN/Total number of patients in series
Negative predictive value  TN/TN  FN
Positive predictive value  TP/TP  FP
TP, True positive; FN, false negative; TN, true negative; FP, false positive.
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Wang needle aspirate of N1 or N2 lymph nodes, 3 had an
anterior mediastinotomy (Chamberlain procedure), and 2
had video-assisted thoroscopy with FNA of suspicious
lymph nodes. The initial disease staging of the patients
before neoadjuvant therapy is shown in Table 2.
Preoperative chemotherapy was administered to all pa-
tients. Thirty-two of the 34 patients received carboplatin and
taxol (Bristol Meyers Squibb). Twenty-seven patients had
preoperative chemotherapy only, and 7 had chemotherapy
and radiotherapy. All 7 patients who received preoperative
radiation received 45 Gy of chest irradiation. Fourteen pa-
tients were enrolled in the American College of Surgeons
Oncology Group S9900 trial. All but 2 patients finished
their planned neoadjuvant treatments. One patient with N2
disease had an allergic reaction to the chemotherapy and,
despite being placed on other chemotherapeutic regimens
and receiving radiation to the chest, had metastasis and did
not have a resection. The second patient refused the final
cycle of his chemotherapy and eventually underwent com-
plete resection. The time interval between the end of the
radiation and the second FDG-PET scan in the 7 patients
who underwent chemotherapy and radiation was a median
of 23 days (range, 10 days–2 years). The time interval
between the last dose of chemotherapy and the second
FDG-PET scan was a median of 23 days (range, 14 days–2
years).
Nine of the 34 patients did not undergo resection. Five
patients with N2 disease had recalcitrant N2 disease. In 3
patients the disease was determined preoperatively through
endoscopic ultrasonography with FNA, and in the other 2
patients the disease was proven at the time of thoracotomy.
Three patients had progression or lack of regression of
disease, had T4 disease at the time of exploratory thoracot-
omy, and did not undergo definitive resection. The final
patient was found to have a metastatic nodule in another
lobe of the same histologic type at the time of thoracotomy
and did not undergo resection (Table 3). The remaining 25
patients underwent pulmonary resection and complete tho-
racic lymphadenectomy. The types of resections were lo-
bectomy in 19 patients, pneumonectomy in 4 patients, and
segmentectomy in 2 patients. All patients who had pulmo-
nary resection also underwent complete thoracic lymphad-
enectomy. The final pathology after chemotherapy, surgical
resection (or both) or restaging is shown in Table 3. One
patient underwent lobectomy, and although the N2 lymph
nodes were all determined to be negative in frozen samples,
he was found to have a microscopic deposit of cancer in one
N2 lymph node on final pathologic examination.
Comparisons were made between the FDG-PET scan
results, the CT scan of the chest and upper part of the
abdomen, and the final pathology results. These results are
summarized in Tables 4 and 5. As seen in these tables,
true-positive, true-negative, false-positive, and false-nega-
tive results were calculated for the residual viable lung
tumor (T status), for N1 lymph nodes stations (ipsilateral
lymph nodes 10, 11, 12, 13, and 14), for paratracheal N2
lymph nodes (ipsilateral nodes 2 and 4), and for the rest of
the N2 lymph nodes (ipsilateral nodes 5, 6, 7, 8, and 9).
From these results, the sensitivity, specificity, accuracy,
positive predictive value, and negative predictive value for
FDG-PET and CT scanning were calculated for each pa-
rameter. These results are shown in Tables 6 and 7.
Statistical analysis shows that FDG-PET scanning when
compared with CT scanning for predicting the presence or
absence of residual cancer in the primary tumor was more
specific (P  .0001), had a higher positive predictive value
(P  .0018), and had a higher negative predictive value
(P  .0001). For the paratracheal lymph nodes, FDG-PET
scanning was more sensitive (P .0001) and more accurate
(P  .0001), had a higher positive predictive value (P 
.0001), and had a higher negative predictive value (P 
.0002) than CT scanning. For the other N2 lymph nodes,
FDG-PET scanning had a higher positive predictive value
than CT scanning (P  .0001).
Discussion
FDG-PET scanning has been studied in thousands of pa-
tients with NSCLC and has been found to be an important
preoperative examination that can detect unsuspected met-
astatic disease and improve patient selection for pulmonary
resection. However, in our experience18 FDG-PET scanning
has a significant number of false-positive results. This
TABLE 2. Initial stage of patients before neoadjuvant che-
motherapy
Stage
No. of
patients
T2 N0 7
T3 N0 8
T4 N0 1
N1 7
N2 11
TABLE 3. Final pathology after neoadjuvant chemotherapy
and after restaging, pulmonary resection, or both
Stage
No. of
patients
T0 N0 4
T1 N0 1
T2 N0 6
T3 N0 7
T4 Nx 3
N1 6
N2 6
Tx Nx M1 1
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seems to be especially true in areas like the Southeast,
where histoplasmosis is endemic. As seen in this trial, when
a baseline FDG-PET scan has been performed and definitive
biopsy specimens of suspicious nodes are performed before
chemotherapy, it is an extremely accurate and noninvasive
test. Although expensive (an FDG-PET scan costs around
$2000 in Birmingham, Ala), it accurately predicts the pres-
ence or absence of recalcitrant malignant disease in the
primary tumor and in the N2 lymph nodes. Perhaps most
important in this series is the fact that the test results were
correct every time for the paratracheal lymph nodes. If
future multicenter trials can corroborate our finding of a
100% negative predictive value for the paratracheal lymph
node, then perhaps FDG-PET scanning can obviate the need
for redo mediastinoscopy, which is a difficult and often
risky procedure. Perhaps patients with a negative FDG-PET
scan result in N2 stations that were previously positive and
involved with cancer might be best served by means of
thoracotomy and frozen-section analysis of the nodes before
resection.
Akhurst and colleagues16 found that FDG-PET scanning
after induction therapy accurately detected viable primary
tumor but not the involvement of mediastinal lymph nodes.
Unlike that study, we compiled data for each lymph node
station and also subdivided the N2 lymph nodes into the
mediastinoscopy-accessible paratracheal nodes versus the
rest of the N2 nodes. Also, in the report by Akhurst and
colleagues, there were 56 patients, although only 14 had an
initial FDG-PET scan before neoadjuvant chemotherapy
that was available for comparison. In our series, similar to
the study of Akhurst and colleagues, most patients had
chemotherapy only, but unlike their series, all of our pa-
tients had an initial FDG-PET scan before the chemotherapy
for comparison.
Careful analysis of Tables 6 and 7 shows that FDG-PET
scanning is at least as good and usually superior to CT
scanning in all categories. It is more specific, has a higher
positive predictive value, and has a higher negative predic-
tive value than CT scanning for detecting residual tumor in
the primary mass. Only FDG-PET scanning correctly pre-
dicted complete resolution of disease in the 4 patients who
had T0 N0 disease (complete responders). When the FDG-
PET scan was incorrect for the T status, it was because it
could not accurately differentiate a T3 lesion from a T2
lesion or it failed to detect a T4 lesion (a small satellite
nodule in the same lobe). FDG-PET scanning could not
differentiate a small satellite T4 lesion in the lung (ie, 5
mm) from a metastatic N1 lymph node. FDG-PET scanning
could not differentiate a T3 tumor with chest wall extension
from a T2 lesion unless the CT scan was viewed concom-
itantly, as it was in this series.
FDG-PET scanning did not offer any significant advan-
tage over CT scanning in the diagnosis of N1 lymph node
metastasis. This is especially true in this series because
patients with T1 small tumors were not included. Most
patients had large bulky T2 or T3 lesions, and these large
tumors obscure the intrapulmonary regional lymph nodes. It
is therefore imperative that FDG-PET scans be reviewed,
along with the current CT scan. In some cases fusion of
functional FDG-PET and anatomic CT images with soft-
ware programs might offer some advantage over visual
correlation. PET-CT systems, which feature a PET and CT
scanner in one machine, are acquired in one sitting for the
patient. They are registered and fused to form a single
3-dimensional image that shows the anatomic location from
the CT scan, along with the metabolic activity of PET. This
type of system might provide the best way to image N1
TABLE 4. Data for true-positive, true-negative, false-posi-
tive, and false-negative results for FDG-PET
Path  Path  Total
PET lung tumor
PET  31 0 31
PET  1 2 3
Total 32 2 34
PET N1 only
PET  2 3 5
PET  9 60 69
Total 11 63 74
PET paratracheal nodes
PET  7 0 7
PET  0 48 48
Total 7 48 55
PET other N2
PET  4 0 4
PET  4 98 102
Total 8 98 106
TABLE 5. Data for true-positive, true-negative, false-posi-
tive, and false-negative results for CT scanning of the chest
and upper abdomen
Path  Path  Total
CT lung tumor
CT  31 2 33
CT  1 0 1
Total 32 2 34
CT N1 only
CT  3 4 7
CT  8 59 67
Total 11 63 74
CT paratracheal nodes
CT  4 1 5
CT  3 47 50
Total 7 48 55
CT other N2
CT  2 1 3
CT  6 97 103
Total 8 98 106
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nodes in the future. Randomized trials of CT-PET scans are
needed.
As described above, perhaps the most important finding
in this series is in patients with N2 disease. Although only
11 patients in this report had N2 disease, repeat FDG-PET
scans correctly predicted the absence or presence of cancer
in all the N2 paratracheal lymph nodes in all patients.
However, as we found in our previous report,18 FDG-PET
scanning is not as accurate in the other N2 stations. It seems
less accurate in the number 5, 6, and 7 lymph node areas.
This is valuable information for the surgeon.
The real question is whether 2 FDG-PET scans are
cost-effective and whether it adds enough information not
given by the repeat CT scan that makes this additional cost
worth it. This article seems to suggest that it is worth it,
although a cost analysis was not performed.
All patients received chemotherapy, and 27 of the 34
patients received chemotherapy only. Because FDG-PET
scanning seems to be sensitive without false-positive results
at any time during chemotherapy, perhaps its true impor-
tance might be to help us tell who is responding to chemo-
therapy after 1 or 2 cycles. Perhaps, in the future, if a patient
is not responding to the preoperative regimen (as deter-
mined by means of repeat FDG-PET scans), then a different
chemotherapeutic regimen, radiation, or both could be
added early in the neoadjuvant therapy. Although we only
had 7 patients who received radiation in this trial and the
numbers were too small to make any solid conclusions,
radiation, in our experience, can lead to a false-positive
FDG-PET result for up to 6 months.
In conclusion, repeat FDG-PET scanning is a highly
accurate noninvasive test that helps predict the T and N2
status in patients with NSCLC who have undergone neoad-
juvant chemotherapy. It is superior to CT scanning in pre-
dicting the absence or presence of residual cancer in the
primary tumor and in N2 nodes, especially paratracheal
lymph nodes. Its role in this setting, especially in patients
with N2 disease, requires further prospective multi-institu-
tional trials.
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Discussion
Dr Douglas E. Wood (Seattle, Wash). Dr Cerfolio, your center
has certainly become one of the leading PET centers for thoracic
malignancies, and I know this is largely due to your own leader-
ship in this area. We all struggle with how to manage patients who
have undergone induction therapy for locally advanced lung can-
cer, particularly those with N2 disease. You are absolutely correct
that the current imaging is very unreliable for determining the
degree of pathologic response. In fact, the error cuts both ways,
with complete radiologic responders having residual microscopic
disease and those with a negligible response sometimes having
complete sterilization of the tumor. Although redo mediastinos-
copy is possible, the risks of the procedure are higher, and the
accuracy is certainly less than expected from the initial mediasti-
noscopy. If we had a test with a very high positive and negative
predictive value, it could potentially obviate the need for invasive
staging or a nontherapeutic thoracotomy. In fact, at one extreme, it
might even allow the avoidance of surgical resection altogether if
we had reliable assurance of a complete pathologic response.
Your own expectations of PET providing this information are
more optimistic than my own. Your series is certainly intriguing
and provides a preliminary indication of efficacy. However, the
knowledge of how PET works makes me skeptical that this will
provide a major clinical benefit. The sensitivity of PET is depen-
dent on tumor cell volume, tumor density, and cellular avidity for
fluorodeoxyglucose. Microscopic disease could easily be missed
with our current technology, resulting in poor sensitivity. On the
other hand, the effects of treatment, particularly radiation, might
produce fluorodeoxyglucose uptake in the absence of tumor, re-
sulting in poor specificity and the tragedy of clinical overstaging.
I note that the majority of your patients had chemotherapy
alone without radiation, and this is partially due to enrollment in
the S9900 clinical trial. However, most centers treat patients with
N2 disease with combination chemoradiotherapy. Do you think
that inclusion of radiation will likely confound the positive pre-
dictive value of PET that you found in this series?
The only other question I have concerns the rationale of sep-
arating out paratracheal lymph nodes from other mediastinal
lymph nodes in your analysis. I know of no evidence from centers
other than yours of a difference in PET accuracy for different N2
nodal stations. I also do not know of evidence that one group of
nodal stations confers a difference in prognosis or treatment rec-
ommendations. Is there a good reason for complicating this anal-
ysis by separating out 2 different sites of N2 nodal disease, and
does this have clinical significance?
Dr Cerfolio. Thank you very much, Dr Wood, for the kind
comments. I appreciate them.
As you mentioned, as a pioneer in some of this PET scan work,
I would like to have some confirmation from other centers to show
that we are either right or way off base, but it would be nice to get
some confirmation. That leads me to your second question first.
We have shown, in the article that we presented at the meeting of
The Society of Thoracic Surgeons this past year on PET scanning,
that PET scanning does seem to have a different accuracy, sensi-
tivity, and specificity in different N2 lymph node stations. Whether
that is important, I do not know, but we do know clinically that
patients with left upper lobe disease that have number 5 and
number 6 N2 involvement have higher survival of especially
adenocarcinomas than those who have N2 disease in a right upper
lobe with number 2 and number 4 involvement. Therefore there
might be clinically important prognostic indicators from that. We
have found that in the number 7, number 5, and number 6 lymph
node stations, PET scanning is a little less accurate than it is in the
number 2 and number 4 stations. I think that answers your second
question first.
Your first question is about the radiation. There is no question
that we have seen that radiation leads to false-positive PET results
up to 6 months and even up to 6.2 months in one patient, so at least
6 months. For that reason, we prefer chemotherapy. We also think
oncologically that chemotherapy is better for patients with N2
disease because it better tests the biology of a patient’s tumor. If
they do not respond to chemotherapy, because most patients with
N2 disease fail systemically, we do not think they should be treated
with resection. Radiation does not test that biology as well as
chemotherapy, and therefore we prefer just chemotherapy for N2
disease, as opposed to chemotherapy and radiation.
Dr Wood. I just want to follow-up on your first answer because
I think that we are talking about 2 different things. With regard to
the aspect of separating lymph node stations out, I agree that for
very specific circumstances, there might be different prognostic
implications of, for example, a station 5 lymph node for a left
upper lobe tumor, but that is not what your article is about. Your
article is about detecting response to therapy, and in your algo-
rithm you have decided to not treat patients surgically that have
persistent N2 disease or any N2 disease. Therefore essentially, it is
an all or none phenomenon, and it does not matter whether it is a
4R lymph node, a 5, a 7, an 8, or a 9. I would ask you again, why
is it necessary to separate those out?
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Dr Cerfolio. The reason we separate out the different lymph
node stations is because we believe the strength of PET is that it
helps inform the surgeon where and how to target biopsies for N2
disease. If it is more accurate in one N2 station compared with
another, then one may choose a mediastinoscopy or an esophageal
ultrasound with FNA over video-assisted thoracic surgery or a
Chamberlain procedure, etc. Also, in the future, we may find a
difference in survival or prognosis; as good scientists, our job is to
present the data. For instance, we may later find that there is a
difference in survival or recurrence patterns for different stations:
for instance, we now know that a positive No. 9 station is a bad
actor. For these reasons we think it is important to report the
difference accuracy for the N2. Another reason is that, unfortu-
nately, not all the patients are seeing surgeons, and a lot of
oncologists are using PET scans to deny people operations. What
we are trying to tell them is to be careful, that all patients need
biopy for all stations, but that in certain stations the PET scan is
even less accurate than it is in others. The bottom line is biopsies
are still needed.
Dr John Benfield (Los Angeles, Calif). If I understood cor-
rectly, you did not proceed with resection when, after induction
therapy, the mediastinal lymph nodes remained positive. That
certainly is a reasonable approach with which I agree. I was not
clear what you do when the intralobar lymph nodes, the N1 lymph
nodes, are positive after induction therapy.
Dr Cerfolio. We perform resection in those patients.
Dr Benfield. Why do you do that?
Dr Cerfolio. Our belief is that it not only improves local
control but potentially improves survival. The jury might be out on
that, but our belief is that it is probably going to lead to improved
survival.
Dr Benfield. I will look forward to additional data on that point
because it is my belief, my hypothesis at least, that after induction
therapy, an N1 lymph node that remains positive is evidence of
systemic disease. I would predict that long-term results will show
that such patients also do not benefit from resection.
Dr Cerfolio. What if the patient started off with an N2 lymph
node? You just asked what do we do with N1, and therefore if they
have been downstaged from N2 to N1, we would resect. If they
have N1 disease and continue to have N1 disease, that is a different
situation. We treat them by resection, but I think that their survival
benefit might be less. I concur.
Dr Benfield. I am just giving you food for thought and a basis
for next year’s article.
Dr Cerfolio. Thank you.
Dr Thomas Rice (Cleveland, Ohio). I want to ask about
microscopic residual disease. How often did you find it, and how
often was PET not able to see it? You have very good sensitivities
and positive predictive values, which means the tumor is still there.
Do you think this is more effective in ineffective chemotherapy
than good PET scanning, and how do you use the information
when your PET scan says that the patient has persistent N2 disease
after induction chemotherapy? Would you perform a biopsy of
those nodes or not perform an operation on that patient?
Dr Cerfolio. I will take the last question first. We do a biopsy
of every node, no matter what the PET scan shows, to determine
whether it is correct or incorrect. If the patient has residual N2
disease, we resect only if the patient is young with low risks and
if we can resect without doing a pneumonectomy.
As to the question about microscopic disease, it depends on
how you define it. If the pathologist very carefully cuts the spec-
imen, one might find microscopic disease and one might not. The
ones where results indicated the patients were complete respond-
ers, we asked them to go back and very carefully cut, and they
found no microscopic disease. Certainly PET scanning is going to
miss microscopic disease of less than 6 mm, and we found that in
this series as well.
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